Business
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of shareholders, originally scheduled to be held on January 16, 2026 (the “Meeting”), to a later date to be announced. Aptose will hold the rescheduled Meeting as soon as practicable in January 2026. No changes are expected to be made to the record date of the Meeting, being the close of busin
About this update from Hanmi Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Aptose Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aptose Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W_19l.RGaQd7rMmL1joc4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b498b08d7b00ed826b23627f4658fc2d","width":300,"height":112}},"lazy":false},{"type":"text","content":"SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of shareholders, originally scheduled to be held on January 16, 2026 (the “Meeting”), to a later date to be announced. Aptose will hold the rescheduled Meeting as soon as practicable in January 2026. No changes are expected to be made to the record date of the Meeting, being the close of business on December 12, 2025, or to the matters to be put before shareholders at the Meeting, including the previously announced continuance of Aptose from the Canada Business Corporations Act to the Business Corporations Act (Alberta) (“ABCA”) (the “Continuance”) and the subsequent acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. (together, the “Hanmi Purchasers”), by way of a statutory plan of arrangement under the ABCA (the “Arrangement” and, together with the Continuance, the “Transaction”).","length":1044,"tagName":"p"},{"type":"text","content":"Aptose has determined to reschedule the Meeting after it receives final clearance of the proxy statement from the United States Securities and Exchange Commission (“SEC”). Following the clearance from the SEC, Aptose will announce the new date, time and virtual details for the Meeting. Aptose intends to mail to all shareholders, and to make available under its profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, the proxy statement, form of proxy, letter of transmittal along with any additional required disclosure in connection with the Meeting.","length":562,"tagName":"p"},{"type":"text","content":"On December 12, 2025, Aptose obtained an interim order from the Court of King’s Bench of Alberta (the “Court”) ...